FDA 510k Submission Process for MedTech Devices: Navigating the Steps

The FDA's 510(k) pathway is used for many devices requiring premarket notification. Eligibility depends on the device and applicable classification, exemptions, and submission rules. Incomplete documentation or unsuitable evidence can delay review. Centralized document control can support consistent preparation; it does not guarantee clearance.

FDA uses the 510(k) process to assess substantial equivalence to a legally marketed predicate device. Check the device classification and applicable exemptions before preparing a submission. eSTAR is required for 510(k) submissions unless exempted; use the applicable FDA instructions for the device and submission type.

Incomplete documentation or inconsistent testing evidence can delay review. Reconcile the device description, intended use, predicate comparison and supporting reports before submission.

A new-generation Document Management System can help MedTech companies reduce these risks by centralizing documentation, enforcing quality workflows and supporting traceability in the configured submission process.

Understanding the 510(k) Process

To receive clearance, a manufacturer must demonstrate substantial equivalence to a legally marketed predicate using the applicable criteria for intended use, technological characteristics, safety and effectiveness. Most Class II devices use this pathway, but some Class II devices are exempt. The required pathway depends on the specific device and classification. Quality-system obligations are separate from the substantial-equivalence determination.

There are three main 510(k) types:

• Traditional 510(k): The standard pathway, supported by full documentation and testing.
• Special 510(k): For eligible modifications to a manufacturer's own legally marketed device, subject to FDA's Special 510(k) criteria.
• Abbreviated 510(k): Leveraging recognized standards and guidance documents to streamline review.

FDA describes a goal of 90 FDA Days for a 510(k) MDUFA decision. FDA Days exclude time on hold for an Additional Information request, so this is not a guaranteed 90-calendar-day clearance period.

While the submission format is standardized, the supporting evidence is unique to each device, meaning document control and traceability are critical.

Common Pitfalls in 510(k) Submissions

FDA separates receipt acknowledgement, format checks and substantive review. Properly prepared eSTAR submissions are not expected to undergo Refuse to Accept review; FDA instead uses virus scanning and technical screening. The 15-day acceptance-review description applies to the eCopy process. An acknowledgement letter confirms receipt and administrative requirements, not clearance. Preparation issues to check include:

• Incomplete or inconsistent documentation between submission sections.
• Required submission documentation missing from the premarket notification.
• Test reports that do not support the applicable performance requirements or a standard or method claimed in the submission.
• Lack of linkage between design history, risk management, and performance data.

During substantive review, FDA may use interactive review or issue an Additional Information request, which places the submission on hold. Its process page describes a Missed MDUFA Communication when no decision has been reached within 100 FDA Days.

Fragmented files and unclear review ownership can make inconsistencies harder to resolve. Assess document-control issues separately from gaps in the scientific or regulatory evidence.

Building a Stronger 510(k) Submission

Medical device manufacturers need a controlled way to assemble the administrative and technical evidence required for their device. Assign a responsible reviewer to each applicable eSTAR section and reconcile information across attachments; there is no universal page count for a 510(k) submission.

Key capabilities might include:

• Centralize the supporting documents, identify the approved version, and use the administrative items required by the applicable FDA submission instructions.
• Link the subject device description, predicate comparison, risk information and relevant performance evidence so reviewers can trace the basis for the submission.
• Using structured review processes to catch inconsistencies well before submission.
• Keeping required quality records ready for review by maintaining a complete version history with time-stamped approvals to support FDA inspections or audits.
• Collaborating effectively without compromising on security, safety and access controls: Enable internal teams and external partners to contribute while preserving document integrity and access controls.

Section-by-section review can identify internal gaps before filing. The responsible regulatory team must still assess the applicable FDA requirements and evidence.

These practices can reduce internal rework. Review time and clearance depend on the device, evidence, and FDA assessment.

Tools That Support Quality and Compliance

Document management can organize approved procedures and quality records for review. FDA's Quality Management System Regulation (QMSR) became effective on February 2, 2026. Assess the records and controls required for the specific manufacturer and device; organizing a dossier does not establish compliance with the QMSR or replace FDA assessment.

AODocs describes document workflows for quality management. A configured system can support version history, review evidence and controlled access to submission records. The manufacturer remains responsible for the evidence, applicable quality-system controls and post-clearance obligations; the software does not establish eligibility or guarantee FDA clearance.

Learn More

• Watch: How AODocs' AI-Powered QMS Works
• Explore AODocs Solutions for Quality Management
• See how AODocs Supports Manufacturing Excellence
• See for yourself: A MedTech company's success story